FARMINGDALE, N.Y., Jan. 13, 2020 -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and.
FARMINGDALE, N.Y., Dec. 05, 2019 -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and.
In 2016 Stavros Vizirgianakis was appointed CEO of Misonix, Inc. (NASDAQ:MSON). This report will, first, examine the...
CryoLife, Inc. ("CryoLife"; NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has entered into an agreement whereby Misonix (NASDAQ: MSON) will have exclusive US commercialization rights for CryoLife's NeoPatch product to treat a broad range of indications outside of cardiac and vascular surgery.
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 5.) Alector Inc (NASDAQ: ALEC ) (announced granting ...
Q1 2020 Misonix Opco Inc Earnings Call
FARMINGDALE, N.Y., May 11, 2020 -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and.
FARMINGDALE, N.Y., Feb. 18, 2020 -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that.
The gross proceeds from this offering are expected to be $30 million, before deducting underwriting discounts and commissions, and offering expenses payable by Misonix. In addition, Misonix has granted the underwriters a 30-day option to purchase up to an additional 243,750 shares of its common stock on the same terms and conditions. Misonix intends to use the net proceeds from the offering for general corporate purposes, which may include investment in sales and marketing initiatives and funding growth opportunities such as collaborations and acquisitions of complementary products or technologies.
At this time, I'd like to turn the conference over to Mr. Norberto Aja, Investor Relations. Thank you for joining the Misonix fiscal 2020 third quarter conference call. Today's call and webcast contain forward-looking statements within the meaning of the safe harbor provision of the US Private Securities Litigation Reform Act of 1995 and can be identified by words such as anticipate, believe, estimate, expect, future, likely, may, should, will and other similar references to future periods.
Q2 2020 Misonix Opco Inc Earnings Call
The Company will host a conference call and webcast at 4:30 p.m. ET that day to review the results. Participants may also listen to a live webcast of the call through the “Events and Presentations” section under “Investor Relations” on Misonix’s website at www.misonix.com. Misonix, Inc. (MSON) designs, manufactures and markets minimally invasive ultrasonic medical devices used for precise bone sculpting, removal of soft and hard tumors and tissue debridement, primarily in the areas of neurosurgery, orthopedic surgery, plastic surgery, wound care and maxillo-facial surgery.
FARMINGDALE, N.Y., May 22, 2020 -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and.
FARMINGDALE, N.Y., Dec. 17, 2019 -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and.
Misonix’s revenue for the three months ended March 31, 2020 was approximately $17.9 million. In the comparable period ended March 31, 2019, Misonix reported revenue of $9.6 million. Due to Misonix’s acquisition of Solsys Medical, which was completed in the first fiscal quarter of 2020, the prior year period revenue excludes TheraSkin revenue of $7.0 million.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 22) 10X Genomics Inc (NASDAQ: TXG ) Abbott Laboratories ...
FARMINGDALE, N.Y., Feb. 05, 2020 -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and.
Based on the fact that hedge funds have collectively under-performed the market for several years, it would be easy to assume that their stock picks simply aren't very good. However, our research shows this not to be the case. In fact, when it comes to their very top picks collectively, they show a strong ability […]
In connection with the offering, Misonix intends to grant the underwriters an option, exercisable for 30 days after the date of the final prospectus supplement, to purchase up to an additional 15% of the shares of its common stock offered in the public offering on the same terms and conditions. Misonix intends to use the net proceeds from the offering for general corporate purposes, which may include investment in sales and marketing initiatives and funding growth opportunities such as collaborations and acquisitions of complementary products or technologies.
FARMINGDALE, N.Y., Jan. 27, 2020 -- Misonix, Inc. (NASDAQ: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and.